

Resource Summary Report

Generated by RRID on Jul 29, 2026

PE/Cyanine7 anti-human CD3

RRID:AB_439781

Type: Antibody

Proper Citation

BioLegend Cat# 300420, RRID:AB_439781

Antibody Information

URL: http://antibodyregistry.org/AB_439781

Proper Citation: BioLegend Cat# 300420, RRID:AB_439781

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_439781

Vendor: BioLegend

Catalog Number: 300420

Alternative Catalog Numbers: 300419

Record Creation Time: 20250820T070848+0000

Record Last Update: 20250821T014157+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD3.

No alerts have been found for PE/Cyanine7 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kurochkin I, et al. (2026) A combinatorial transcription factor screening platform for immune cell reprogramming. *Cell systems*, 101457.

Zheng D, et al. (2025) CD4+ anti-TGF- β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects. *Cell reports. Medicine*, 6(3), 102020.

Schlautmann L, et al. (2025) Glucose tasting depletes intracellular calcium stores and impairs macrophage functionality. *iScience*, 28(11), 113770.

Zeng J, et al. (2025) Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. *Cell stem cell*, 32(2), 191.

Tano-Menka R, et al. (2024) Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules. *Structure (London, England : 1993)*, 32(8), 1121.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ 2a. *Cell*, 187(5), 1238.

Zhang C, et al. (2024) Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression. *Developmental cell*, 59(23), 3072.

Ingels J, et al. (2024) Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. *Cell reports. Medicine*, 5(5), 101516.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. *Cell reports. Medicine*, 5(2), 101400.

Zhu X, et al. (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. *Cancer research*, 84(1), 84.

Tachi T, et al. (2024) Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. *Cancer immunology, immunotherapy : CII*, 73(12), 256.

Povoleri GAM, et al. (2023) Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets. *Cell reports*, 42(5), 112514.

Zeng J, et al. (2023) Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. *bioRxiv : the preprint server for biology*.

Peterson JJ, et al. (2023) A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells. *Cell chemical biology*, 30(12), 1617.

Vazquez-Lombardi R, et al. (2022) High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. *Immunity*, 55(10), 1953.

Vijayakumar B, et al. (2022) Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. *Immunity*, 55(3), 542.

Teng F, et al. (2021) ILC3s control airway inflammation by limiting T cell responses to allergens and microbes. *Cell reports*, 37(8), 110051.

Andreano E, et al. (2021) Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. *Cell*, 184(7), 1821.

Cazzetta V, et al. (2021) NKG2A expression identifies a subset of human V α 2 T cells exerting the highest antitumor effector functions. *Cell reports*, 37(3), 109871.

Nagpal N, et al. (2020) Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. *Cell stem cell*, 26(6), 896.